Abstract: Compounds of general Formula I ##STR1## wherein Z.sup.1 and Z.sup.2 in each case independently mean the residue--(CH.sub.2).sub.m --(C.sub.6 H.sub.4).sub.q --(O).sub.k --(CH.sub.2).sub.n --(C.sub.6 H.sub.4).sub.l --(O).sub.r --R,whereinm and n means the numbers 0-20,k, l, q and r means the numbers 0 and 1, andR means a hydrogen atom, an optionally OR.sup.1 -substituted C.sub.1 -C.sub.6 -alkyl residue, or a CH.sub.2 COOR.sup.1 group with R.sup.1 meaning a hydrogen atom, a C.sub.1 -C.sub.6 -alkyl residue, or a benzyl group,with the proviso that at least two substituents X stand for a metal ion equivalent; that one of the substituents Z.sup.1 and Z.sup.2 stands for a hydrogen and the other is not H; that--if n and l each means the number 0--k and r do not simultaneously mean the number 1; that --(O).sub.r --R is not --OH; and that Z.sup.1 and Z.sup.2 are not --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOCH.sub.2 C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.5 --COOCH.sub.2 C.sub.6 H.sub.

Abstract: Photodynamic therapy of conditions of the eye, especially those conditions characterized by unwanted neovasculature, such as age-related macular degeneration, results in enhanced visual acuity for treated subjects,

Abstract: In accordance with the present invention, there are provided methods for the in vivo reduction of nitric oxide levels in a mammalian subject. In contrast to the inhibitory approach described in the prior art (i.e., wherein the function of the enzymes responsible for nitric oxide production is inhibited), the present invention employs a scavenging approach whereby overproduced nitric oxide is bound in vivo to a suitable nitric oxide scavenger. The resulting complex renders the nitric oxide harmless, and is eventually excreted in the urine of the host. Further in accordance with the present invention, there are provided compositions and formulations useful for carrying out the above-described methods. An exemplary nitric oxide scavenger contemplated for use in the practice of the present invention is a dithiocarbamate-ferrous iron complex. The present invention relates to methods for reducing in vivo levels of .multidot.NO as a means of treating subjects afflicted with inflammatory and/or infectious disease.

Abstract: A method for measuring temperature and/or pH in vivo using paramagnetic compounds, e.g., lanthanide complexes, in conjunction with NMR has been developed. The chemical shift of the nuclear spin in these complexes can then be correlated to temperature. This non-invasive temperature measurement method is particularly useful in monitoring temperature of cancerous tissue during hyperthermic treatment to destroy the cancerous tissue or tumor.

Abstract: The invention relates to new diethylenetriaminepentaacetic acid derivatives, their complexes and complex salts, that contain an element of atomic numbers 20-32, 39-51 or 57-83, pharmaceutical agents that contain these compounds and their use as contrast media and antidotes.

Abstract: The present invention employs a scavenging approach whereby overproduced nitric oxide is bound in vivo to a suitable nitric oxide scavenger. The resulting complex renders the nitric oxide harmless, and is eventually excreted in the urine of the host. Further in accordance with the present invention, there are provided compositions and formulations useful for carrying out the above-described methods. An exemplary nitric oxide scavenger contemplated for use in the practice of the present invention is a dithiocarbamate-ferrous iron complex. This complex binds to .NO, forming a stable, water-soluble dithiocarbamate-iron-NO complex having a characteristic three-line spectrum (indicative of a mononitrosyl-Fe complex) which can readily be detected at ambient temperatures by electron paramagnetic resonance (EPR) spectroscopy. The present invention relates to methods for reducing in vivo levels of .NO as a means of treating subjects afflicted with inflammatory and/or infectious disease.

Abstract: The present invention relates to the use of paramagnetic materials, such as lanthanide chelates, as contrast agents in magnetometric analysis, especially imaging. The invention is particularly directed to structural and functional diagnosis or imaging.

Abstract: The invention relates to complex compound as well as their salts consisting of at least one metal ion and one complexing agent of general formula I ##STR1## in which Z.sup.1, Z.sup.2 and s have different meanings, as well as their use for the production of agents for radiation therapy and for NMR diagnosis and diagnostic radiology, especially for contrasting the hepatobiliary system. Further, the invention relates to a process for the production of these compounds and agents.

Abstract: According to the present invention, an antianemic agent for the treatment of anemia caused by iron-deficiency containing iron and difructose. Iron and difructose contained in the said antianemic agent may form a complex, and their appropriate molar ratio is within the scope of 1:0.5 to 1:1000.Further, the antianemic agent in accordance with the present invention may additionally contain hematopoietics such as cyanocobalamine, pyridoxine hydrochloride, folic acid, etc.

Abstract: The invention provides antioxidant salen-metal complexes, compositions of such antioxidant salen-metal complexes having superoxide activity, catalase activity, and/or peroxidase activity, compositions of salen-metal complexes in a form suitable for pharmaceutical administration to treat a disease associated with cell or tissue damage produced by free radicals such as superoxide, and cosmetic and free radical quenching formulations of salen metal compounds.

Abstract: 1. Compounds of general Formula I ##STR1## wherein n and m in each case mean the numbers 0, 1, 2, 3 and 4,X stands for a hydrogen atom and/or a metal ion equivalent of an element of atomic numbers 21-29, 31, 32, 37-39, 42-44, 49 or 57-83,R.sup.1 and R.sup.2, being different, mean in each case a hydrogen atom or a straight-chain, branched, saturated or unsaturated C.sub.0 -C.sub.20 -alkylene group, this alkylene group exhibiting at the end either a second molecule of general Formula I.sub.A or I.sub.

Abstract: Diethylenetriaminepentaacetic acid monoamide derivatives, their complexes and complex salts, containing an element of atomic numbers 21-29, 31, 32, 39, 42-44, 49 or 57-83, pharmaceutical agents containing these compounds, their use as contrast media and process for their production.

Abstract: Metal complexes containing a metal of atomic numbers 39-42, 44-51 or 56-83 and a complexing agent can be used for the production of contrast media for use in the contrast-enhanced computer tomography of the liver and the biliary tracts.

Abstract: The present invention relates to dietary supplements for supplementing the dietary needs of women and preventing or reducing life stage associated health risks during each of their principal adult life stages (pre-perimenopause, perimenopause and menopause, or post-menopause).

Abstract: A method of electrical impedance imaging (EII) of a subject comprising administering an EII sensitive contrast agent and generating an electrical impedance image of at least part of the subject.

Abstract: A medical food having the below listed components is administered for several days as the sole source or as a substantial source of the daily caloric intake of a patient suffering from metabolic poisoning: 45 to 65% protein concentrate; 2.5 to 17.5% of grain syrup solids containing 50% dextran; 2.5 to 17.5% of grain syrup solids containing 50% of maltose; 3 to 12% of oil containing 20% of oleic acid, 1 to 11% medium chain triglycerides; magnesium ions; buffering agent; soluble calcium salt; ascorbic acid; 0.40 to 0.65% of .beta. carotene; D-.alpha.-tocopherol; chromium ions in the trivalent or hexavalent form, 0.008 to 0.022% glutathione, 0.08 to 0.22% N-acetylcysteine; L-lysine hydrochloride; 0.08 to 0.22% L-threonine, and 0.08 to 0.22% of L-cysteine.

Abstract: The present invention relates to the use of paramagnetic materials, such as lanthanide chelates, as contrast agents in magnetometric analysis, especially imaging. The invention is particularly directed to structural and functional diagnosis or imaging.

Abstract: Novel contrast media for use in magnetic resonance imaging are described. Such contrast media are comprised of biocompatible polymers either alone or in admixture with one or more contrast agents such as paramagnetic, superparamagnetic or proton density contrast agents. Additionally, the polymers or polymer and contrast agent admixtures may be mixed with one or more biocompatible gases to increase the relaxivity of the resultant preparation, and/or with other components. In a preferable embodiment, the contrast medium is hypoosmotic.

Abstract: Calixarene conjugates useful for imaging, particularly magnetic resonance imaging (MRI) and computed tomography (CT) are described. Said calixarene conjugates comprise (i) a calixarene backbone, and (ii) at least one imaging moiety linked thereto, and may be of the formula: ##STR1## wherein at least one of the R.sup.1 and R.sup.4 substituents comprises an imaging moiety, the remaining R.sup.1 and R.sup.4 substituents are spectator groups, J is an ortho-linker, and n is an integer from 4 to 8. Imaging moieties useful for CT imaging include those comprising two or more iodine atoms. Imaging moieties useful for MRI include (i) organic moieties comprising four or more fluorine atoms; (ii) nitroxyl spin labeled moieties; and (iii) metal chelate moieties.

Abstract: Emulsions of paramagnetic contrast agents, and processes of making and using them are disclosed. The emulsions contain water, a dispersed oil phase and a complex of a paramagnetic metal ion and an organic acid chelator, for example DTPA (diethylenetriaminepentaacetic acid), having a C.sub.10 -C.sub.30 saturated aliphatic group and an hydroxyl group bonded to the nitrogen atom. The emulsions are very stable and therapeutically acceptable for intravenous administration to enhance MRI imaging.

Abstract: A method of treating skeletal muscle fibrosis in mammals. The novel method is effective for reducing the extent of skeletal muscle fibrosis in an individual who suffers from a disorder which targets skeletal muscle tissue, such as Duchenne's and Becker's muscular dystrophy and denervation atrophy induced by either trauma or neuromuscular disease. The treatment includes administering to the individual an effective amount of a metalloporphyrin compound, especially hemin, heme arginate, cobalt protoporphyrin IX chloride and cobalt protoporphyrin IX arginate.

Abstract: Mineral absorption is promoted in warm-blooded animals by means of a class of 1,2-disubstituted aromatic mineral chelates wherein the 1 and 2 substituents each donates a pair of electrons to a metal ion for formation of a five-member chelate ring. 2-Alkoxyphenols are particularly preferred. The chelates contain from one to three alkoxyphenol ligands, with two ligands being preferred. A preferred alkoxyphenol is vanillin, and the minerals are selected from the group consisting of Mg, Ca, Cr, Mn, Fe, Co, Cu, Zn, Mo, and Se. Vanillin metal chelates have a slight to neutral taste, and are absorbed more readily than inorganic mineral salts.

Abstract: A compound of the following formula ##STR1## wherein m is an integer of 1 to 3, R.sub.1 and R.sub.2 are the same or different and each is hydrogen atom or lower alkyl, and R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are the same or different and each is hydroxy or a group of the formula ##STR2## (wherein n is 0 or 1, X is --NH-- or --O--, Y is alkylene, A is hydrogen atom, lower alkyl, lower alkoxy, halogen atom or trifluoromethyl, and B is alkyl or alkenyl), with the proviso that two or three of R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are hydroxyl groups and that when two of them are hydroxyl groups, the cases where R.sub.3 and R.sub.5 are hydroxy, and R.sub.4 and R.sub.6 are hydroxy are excluded; a complex compound comprising said compound and a metallic atom; and a diagnostic agent containing said complex compound. The above compound is useful as a chelating agent and the complex compound comprising said compound and a metallic atom exhibits superior characteristics as a contrast medium for image diagnosis.

Abstract: Emulsions of paramagnetic contrast agents, and processes of making and using them are disclosed. The emulsions contain water, a dispersed oil phase and a complex of a paramagnetic metal ion and an organic chelator having a C.sub.10 -C.sub.30 unsaturated aliphatic group. The emulsions are very stable and therapeutically acceptable for intravenous administration to enhance MRI.

Abstract: The present invention relates to the preparation of amino-acyl-type and catecholamine-type compounds having multiple carboxylic acid functional groups. Paramagnetic metal (II) or (III) ion chelate complexes are formed using these compounds for use as intravenous contrast agents to produce enhanced contrast magnetic resonance images of the heart, liver, biliary tree or upper small intestine. The mono- and di-amino acids, their esters and amides, and catecholamine-like derivatives, of EDTA, DTPA, and the like are prepared. The paramagnetic metal (II) or (III) ion complexes are formed and produce T1-related contrast effects in MR images. The compounds and complexes also appear to have low toxicities and to be relatively rapidly and completely cleared from the tissue of a living mammal, e.g. a human being.

Abstract: Novel magnetic resonance imaging agents comprise complexes of paramagnetic ions with hydrazide derivatives of polyaminocarboxylic acid chelating agents. These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions. A novel method of performing an NMR diagnostic procedure involves administering to a warm-blooded animal an effective amount of a complex as described above and then exposing the warm-blooded animal to an NMR imaging procedure, thereby imaging at least a portion of the body of the warm-blooded animal.

Abstract: An NMR contrast agent composition contains a complex of a selected metal ion and a selected ligand.

Abstract: A diagnostic composition comprising a binuclear complex between a polyaminopolycarboxylic ligand, such as diethylene triamine pentacetic acid, a paramagnetic metal such as Gd and an endogenous metal such as Ca, optionally mixed with the mononuclear complex of the same paramagnetic metal and the same ligand. This composition can be used as a contrasting agent in magnetic resonance imaging.

Abstract: A water soluble metal amino acid chelate is prepared by adding a metal salt to deaerated water, mixing the salt solution with a mixture of an amino acid and an organic acid and adjusting the pH of the resulting composition to a range of from about 4.5 to about 8.5 to produce a clear solution. The resultant clear solution can then be applied to plants or it can be dried for storage. The water soluble metal amino acid chelate produced by the process, when applied to plants, results in increased metals assimilation and improved plant growth.

Abstract: A second sphere contrast enhancing agent for magnetic resonance imaging comprises a paramagnetic metal ion having catecholate ligands coordinated thereto and having water molecules hydrogen bonded to the catecholate ligands.

Abstract: The invention provides a method of monitoring the vasodilatory or vasoconstrictive effects of a physiologically active substance administered to a human or non-human animal body, said method comprising the steps of: administering said substance into said body; administering into the systemic vasculature of said body a contrast enhancing amount of an intravascular paramagnetic metal containing magnetic resonance imaging contrast agent; subjecting said body to a magnetic resonance imaging procedure capable of generating from magnetic resonance signals from said body a series of temporally spaced images of at least a part of said body into which said agent passes, said procedure being a fast imaging procedure having an image acquisition time of less than five seconds; and detecting temporal variations in said signals or images whereby to monitor the vasoconstriction or vasodilation induced by said substance.

Abstract: 1. Compounds of general Formula I ##STR1## wherein n and m in each case mean the numbers 0, 1, 2, 3 and 4,X stands for a hydrogen atom and/or a metal ion equivalent of an element of atomic numbers 21-29, 31, 32, 37-39, 42-44, 49 or 57-83,R.sup.1 and R.sup.2, being different, mean in each case a hydrogen atom or a straight-chain, branched, saturated or unsaturated C.sub.0 -C.sub.20 -alkylene group which optionally contains imino, phenylenoxy, phenylenimino, amido, hydrazido, ester group(s), oxygen, sulfur and/or nitrogen atom(s) and is substituted, if desired, by hydroxy, mercapto, imino, epoxy, oxo, thioxo and/or amino group(s), this alkylene group exhibiting at the end either a second molecule of general Formula I.sub.A or I.sub.B ##STR2## a functional group, or, linked by way of this functional group, a bio- or macromolecule,are valuable diagnostic and therapeutic media.

Abstract: The present invention provides compounds of the formula ##STR1## chelated with a paramagnetic metal ion wherein Z1 and Z2 each represent the atoms necessary to complete a monocyclic or polycyclic carbocyclic or heterocyclic ring system, said Z1 and Z2 independently optionally substituted with R.sup.6 and R.sup.7, respectively;R.sup.l, R.sup.2, R.sup.3 and R.sup.4 are independently carboxyalkyl (C.sub.1 -C.sub.2), --(CH.sub.2).sub.n --C(.dbd.O)--NH--R.sup.8, or --(CH.sub.2).sub.n --C(.dbd.O)--O--R.sup.8R.sup.5 is carboxyalkyl (C.sub.1 -C.sub.2);R.sup.6 and R.sup.7 are independently hydrogen, benzyl, or benzyloxy, said benzyl or benzyloxy optionally substituted with one, two or three substituents selected from the group consisting of amino, isocyanato (--N.dbd.C.dbd.O), isothiocyanato (--N.dbd.C.dbd.S), --NH--C(.dbd.O)--X or --NH--C(.dbd.S)--X;R.sup.8 is alkyl (C.sub.1 -C.sub.20), --(CH.sub.2).sub.m --Ar, or polyhydroxyalkyl (C.sub.1 -C.sub.

Abstract: SOD for treating hair loss is disclosed. The SOD has utility in a topical pharmaceutical formulation for the cosmetic treatment of hair loss and the cosmetic stimulation of hair growth. The SOD comprises copper salicylate, copper aspirinate, indomethacin-copper, or a complex of an amino acid or peptide and a transition metal.

Abstract: Methods wherein the concentration of NMR-detectable xenobiotic compounds may be determined in living subjects by in vivo measurement of one or more magnetic resonance signals. In preferred embodiments, the present invention provides a method for evaluating, in vivo, the clearance rate of a xenobiotic compound from a living subject, thereby providing a noninvasive method for determining the status of the excretory organs of the subject, and a method for determining the proper dosing regimen of a pharmacologically active compound to be administered to the subject.

Abstract: Novel complexes of paramagnetic ions and compounds bearing long acyl chains have been synthesized as magnetic resonance imaging contrast agents. These novel liposoluble contrast agents may be administered alone, or with lipids, suspending agents or other additives. The lipids may be in the form of liposomes, micelles or lipid emulsions. The contrast agents of the invention have particular use in magnetic resonance imaging of the liver, blood pool and reticuloendothelial system.

Abstract: A polymeric contrast enhancing agent for magnetic resonance images having a chelating agent, which can be bound to metal ions having at least one unpaired electron, such as gadolinium. Examples of such chelating agents include DTPA-ethylenediamide-methacrylate copolymer and poly-(DTPA-ethylenediamide). These contrast enhancing agents, bound to the metal ions, are then administered to a patient, and following this the MR images are taken.

Abstract: The present invention relates to contrast enhancing agents, conjugates thereof, pharmaceutical compositions thereof, and methods for diagnostic analysis, particularly NMR image analysis using these agents. The contrast enhancing agents are chelates of paramagnetic, ferromagnetic or diamagnetic metal ion(s) complexed with new lipophilic complexing acids related to polyaminopolycarboxylic acids.

Abstract: A compound of the following formula ##STR1## wherein m is an integer of 1 to 3, R.sub.1 and R.sub.2 are the same or different and each is hydrogen atom or lower alkyl, and R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are the same or different and each is hydroxy or a ##STR2## (wherein n is 0 or 1, X is --NH-- or --O--, Y is alkylene, A is hydrogen atom, lower alkyl, lower alkoxy, halogen atom or trifluoromethyl, and B is alkyl or alkenyl), with the proviso that two or three of R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are hydroxyl groups and that when two of them are hydroxyl groups, the cases where R.sub.3 and R.sub.5 are hydroxy, and R.sub.4 and R.sub.6 are hydroxy are excluded; a complex compound comprising said compound and a metallic atom; and a diagnostic agent containing said complex compound. The above compound is useful as a chelating agent and the complex compound comprising said compound and a metallic atom exhibits superior characteristics as a contrast medium for image diagnosis.

Abstract: A pharmaceutical composition in dosage form for treating psoriasis and psoriatic arthritis includes, essentailly, as active substance (s), a fumaric acid monoalkylester salt having the formula ##STR1## wherein R is a methyl, propyl or isopropyl group, and M.sup.++ is calcium, alone or in combination with at least one of the fumaric acid alkyl ester salts as defined above, M.sup.++ is selected from the group consisting of magnesium, zinc and iron. The combination includes, by weight, 10-250 parts, 0-50 parts magnesium, and 0-50 parts zinc or iron salt of fumaric acid monoalkylester, in an amount of fumaric acid not exceeding 300 mg. per dosage form, in combination with ordinary pharmaceutically compatible solid adjuvants and vehicles.

Abstract: Fungal nail infections are treated by depriving aerobic fungi of oxygen by forming an oxygen barrier over the exposed surface of an infected nail. Conveniently, the oxygen barriers are formed by applying a liquid film-forming carrier comprising an oxygen-scavenging substance, such as transition metal chelate or complex of salicylic acid or a salicylate, an oxidizable organic acid or alcohol in combination with a catalyzing agent, or a polycarboxylic acid chelate or complex of a transition metal or transition metal salt.

Abstract: Blood coagulation is accelerated by contacting blood with an accelerator of hydrolase activity. The activation of the precursors of serine protease including Factor XII and the enzyme activity of serine protease is accelerated. The accelerator is a metal complex containing a ligand which is a cyclic compound having a five- or six-membered ring containing carbonyl groups adjacent to each other. Examples of such ligands are oxidized alkylgallate, partially or totally oxidized ellagic acid, partially or completely oxidized 1,4- di(3,4-dihydroxyphenyl) 2,3-dimethylbutane, 1,2,3-triketohydroindene and isatin. The metal of the complex is preferably Fe, Co, Ni, or Al. The complex may be combined with a hydrolase as a co-accelerator of coagulation, an organic acid having an amino salt and/or a quaternary nitrogen or an antifibrinolysis agent and/or an anti-plasmin agent.

Abstract: Nuclear magnetic resonance (NMR) imaging of body organs and tissues is enhanced by administering to a living animal body a diagnostic composition comprising a diagnostically effective amount of a substantially nontoxic paramagnetic image altering agent containing a chelate of a paramagnetic element such as magnesium, gadolinium or iron, carried by a liposome. The chelate is carried by or within or outside the external surface of the liposome in such a manner that after arrival at or delivery to the desired organ or tissue site, the paramagnetic image altering agent is released in a diagnostically useful fashion.

Abstract: Hybrid agents for enhancing in vivo diagnostic imaging of body organs and tissues, and methods of preparing and using the same.

Abstract: A wood preservative composition including a mixture of two or more metallic soaps of long chain unsaturated fatty acids, which soaps have a metallic component selected from the group consisting of copper, zinc, chromium, iron, antimony, tin, cobalt, nickel, arsenic, boron, lead, magnesium, potassium and sodium, and a fatty acid component selected from two or more of the group consisting of oleic acid, linoleic acid, and linolenic acid, the composition being such that the ratio by mass of metallic soap of oleic acid:metallic soap of linoleic acid:metallic soap of linolenic acid is about 20-29:15-70:0-47.

Abstract: Complex compounds of general Formula I ##STR1## wherein X is a hydrogen atom and/or a metal ion equivalent of at least one element of atomic numbers 21-29, 42, 44 or 58-70, with at least two of the substituents X representing a metal ion equivalent, andR.sup.1, R.sup.2, R.sup.3, R.sup.4, Y and n are defined herein, as well as their salts with organic and/or inorganic bases, are valuable compounds for organ-specific NMR diagnostics.

Abstract: A coating composition for application to tree wounds, such as pruning wounds of living trees is provided. The composition is non-phytotoxic and provides extended protection against fungal pathogens. The coating composition comprises a liquid carrier together with a fatty acid metal salt active ingredient. Exemplary fatty acid metal salts include those prepared from alpha monocarboxylic acids having from 4 to 18 carbon atoms and a compound containing a metal selected from the group consisting of calcium, copper, iron, magnesium, and zinc. Various additives can be included within the composition, including gum-like substances and binders suitable to facilitate the adhesion of the active ingredient to the tree surface, as well as defoaming agents and other formulation enhancing agents.

Abstract: Methods for removing ferric iron from aqueous liquids and for performing deferration therapy are disclosed, involving the use of a novel siderophore, termed anguibactin. Anguibactin is isolated from a marine pathogen, Vibrio anguillarum, containing the pMJ1 plasmid. Anguibactin inhibits iron uptake by living cells, wrests iron from vertebrate tissues, removes iron from other siderophores and ferric hydroxide, and removes ferric iron from aqueous solutions, including cell-culture media. For deferration therapy, anguibactin from which bound iron has been removed is administered by dissolving in water or other liquid aqueous pharmaceutical carrier at a dosage typical for other siderophores. Anguibactin is preferably administered intramuscularly or subcutaneously, but can be given intravenously.

Abstract: Methods and compositions are disclosed for enhancing .sup.19 F magnetic resonance imaging which utilize trifluoromethyl derivatives of iodinated X-ray contrast media. Typical magnetic resonance contrast media within the scope of the present invention include bis(trifluoromethyl)benzene derivatives, tris(trifluoromethyl)benzene derivatives, tetrakis(trifluoromethyl)benzene derivatives, and other related trifluoromethylated benzene derivatives.

Abstract: Disclosed herein are copper based fungicidal and bactericidal compositions having enhanced activity against fungi and bacteria, methods of using such compositions as well as methods for increasing the effectiveness of the copper based fungicidal and/or bactericidal compounds employed in such compositions. An aggregation inhibiting salt is included within these compositions to prevent aggregate and/or sediment formation upon the addition of Fe.sup.+3 to the composition.